Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03970616 · ClinicalTrials.gov registry record · Phase 1
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
A Phase 1 study, sponsored by AVEO Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT03970616 is a Phase 1 study that was terminated before completion, run by AVEO Pharmaceuticals. The registered enrollment target is 27 participants.
The verdict
NCT03970616, a Phase 1 study, was terminated before completion, sponsored by AVEO Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.
Interventions
- DRUG Durvalumab
- DRUG Tivozanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03970616
The ClinicalTrials.gov registry entry for NCT03970616 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AVEO Pharmaceuticals, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Durvalumab is the first listed.
NCT03970616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03970616 about?
NCT03970616 is a clinical study titled "A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma". This study will evaluate the safety, tolerability, DLTs, MTD, and preliminary anti tumor activity of tivozanib in combination with durvalumab in subjects with advanced HCC.
What is the current status of trial NCT03970616?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2019-09-30. Estimated completion is 2023-04-04.
What interventions are being tested in trial NCT03970616?
The interventions under investigation include: Durvalumab (DRUG), Tivozanib (DRUG).
Who is sponsoring clinical trial NCT03970616?
This trial is sponsored by AVEO Pharmaceuticals, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.